Rosetta Genomics Identifies Potential microRNA Biomarkers in B...( The Study Demonstrates microRNAs Ex...),Health

The Study Demonstrates microRNAs Extracted From a Simple Blood Draw Have the Potential to Serve as Effective Clinical Biomarkers for a Wide Range of

Indications Using This Proprietary Technology, Rosetta Genomics is Currently Developing

a Blood-Based Test to Detect Colon Cancer

REHOVOT, Israel and JERSEY CITY, New Jersey, September 5 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today that the results of a study conducted by its scientists describing the identification of microRNA biomarkers in blood serum, have been published online in the peer-reviewed journal PLOS One. The findings demonstrate that microRNAs have the potential to be used as clinical biomarkers for a wide range of indications in cancer and women's health.

Using its proprietary extraction and quantification methods, Rosetta Genomics is now advancing the development of a blood-based test which will utilize microRNAs to detect patients with colon cancer.

"This study further validates our understanding that microRNAs may be used as clinical biomarkers for a wide range of indications, both through invasive and non-invasive methods," noted Dr. Dalia Cohen, Chief Scientific Officer of Rosetta Genomics. "The results of this study are the basis of one of our development programs to detect colon cancer via microRNAs identified in serum. I believe our strong scientific capabilities will continue to produce exciting studies, which we will share once available."

The paper, "Serum MicroRNAs are Promising Novel Biomarkers" is now available on PLOS One website on http://dx.plos.org/10.1371/journal.pone.0003148

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators a
'/>"/>